Bogart Wealth LLC Purchases 2,973 Shares of Danaher Co. (NYSE:DHR)

Bogart Wealth LLC boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 13.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 25,746 shares of the conglomerate’s stock after purchasing an additional 2,973 shares during the quarter. Bogart Wealth LLC’s holdings in Danaher were worth $5,956,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. BKM Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher in the 4th quarter valued at approximately $29,000. OFI Invest Asset Management acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $30,000. Rakuten Securities Inc. bought a new stake in shares of Danaher during the fourth quarter valued at approximately $36,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Danaher in the fourth quarter valued at $41,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 0.2 %

Shares of NYSE DHR traded up $0.40 during mid-day trading on Thursday, hitting $249.95. The company’s stock had a trading volume of 191,139 shares, compared to its average volume of 2,701,168. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company’s fifty day simple moving average is $248.27 and its 200-day simple moving average is $233.19. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The stock has a market cap of $185.13 billion, a price-to-earnings ratio of 42.30, a price-to-earnings-growth ratio of 3.82 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s revenue was down 2.6% on a year-over-year basis. During the same period last year, the company earned $2.36 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

DHR has been the topic of several analyst reports. Citigroup boosted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. KeyCorp upped their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. HSBC raised Danaher from a “hold” rating to a “buy” rating and boosted their price target for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, TD Cowen upped their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $267.31.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 103,984 shares of company stock worth $25,997,094 in the last quarter. Corporate insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.